CMS Takes Sides in the Statin Wars
This article was originally published in RPM Report
The Centers for Medicare & Medicaid Services is showing a lot more interest in ensuring broad access to low-cost generic drugs now that the agency is overseeing the implementation of Medicare Part D. As evidence of this trend, CMS considered weighing in on a court decision regarding the availability of Zocoor generics.
You may also be interested in...
Medicare Part D and prescription drug prices come up briefly in a brief appearance by controversial CMS head Berwick before the Senate Finance Committee.
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
A brief summary of recent clinical developments impacting the medical device industry, including limb regeneration, NIH's research plan for Type I diabetes, heart failure and statins; and new glaucoma research.